which along with PNH and IgAN include atypical haemolytic uraemic syndrome (aHUS), C3 glomerulopathy (C3G), and idiopathic membranous nephropathy (IMN). IgAN is a key focus for Novartis ...

The kidney damage from C3 glomerulopathy happens when your body’s complement system goes into overdrive. Here’s how it impacts your kidneys.

Novartis is cueing up a new indication in the US for its oral therapy for complement-mediated diseases – Fabhalta – after reporting new data with the drug in ultra-rare kidney disease C3 ...

His brother James, 14, was found to have C3 glomerulonephritis (C3GN) last year and now has to take eight pills a day to control the rare disease, which affects his kidneys. Those taking part on ...